Abcellera Biologics Inc (ABCL)

$3.88 +0.02 (0.52%)
Market Cap 1.14B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 2,044,406
Avg Vol 3,363,638
Day's Range N/A - N/A
Shares Out 303.16M
Stochastic %K 94%
Beta 0.85
Analysts Strong Sell
Price Target $9.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
_TeamArctic
_TeamArctic Apr. 16 at 5:56 PM
$ABCL $TGTX $INTC $BULL KA
0 · Reply
DragonAlgo
DragonAlgo Apr. 16 at 5:45 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com
1 · Reply
8008track
8008track Apr. 16 at 4:21 PM
$ABCL Sounds bananas but AbCellera has a better than zero chance to 100x in the next 10-20 years. The daily price movement would be greater than today’s price.
0 · Reply
DeMampCamp
DeMampCamp Apr. 16 at 3:58 PM
$ABCL Shorts are desperately trying to keep this under $4, I feel the flood gates are about to break if we can get past the low $3.90S !! Cheers everyone!
1 · Reply
tradersunion353
tradersunion353 Apr. 16 at 2:44 PM
$ABCL now those adding loading guys will showup cheerleading 😂😂😂
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 16 at 1:49 PM
$ABCL South Korea likes $ABCL https://x.com/nick88886666/status/2044669284224483720?s=20
0 · Reply
Targhee
Targhee Apr. 16 at 1:46 PM
$ABCL enough is enough…BLOCKED!!
2 · Reply
tradersunion353
tradersunion353 Apr. 16 at 1:44 PM
$ABCL market is trading at record highs meanwhile this pos overhyped stock cannot even move a penny .
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 16 at 1:42 PM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 16 at 1:41 PM
$ABCL Truist on $ABCL https://x.com/jinseongeo83473/status/2044693047402004887?s=20
0 · Reply
Latest News on ABCL
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 14 days ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 7 weeks ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 2 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 3 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 4 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 4 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 5 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 5 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 7 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 8 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

AbCellera Announces Resignation of Board Member

Feb 23, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Resignation of Board Member

AbCellera to Present at Upcoming Investor Conferences in March

Feb 22, 2024, 8:15 PM EST - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in March

_TeamArctic
_TeamArctic Apr. 16 at 5:56 PM
$ABCL $TGTX $INTC $BULL KA
0 · Reply
DragonAlgo
DragonAlgo Apr. 16 at 5:45 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com
1 · Reply
8008track
8008track Apr. 16 at 4:21 PM
$ABCL Sounds bananas but AbCellera has a better than zero chance to 100x in the next 10-20 years. The daily price movement would be greater than today’s price.
0 · Reply
DeMampCamp
DeMampCamp Apr. 16 at 3:58 PM
$ABCL Shorts are desperately trying to keep this under $4, I feel the flood gates are about to break if we can get past the low $3.90S !! Cheers everyone!
1 · Reply
tradersunion353
tradersunion353 Apr. 16 at 2:44 PM
$ABCL now those adding loading guys will showup cheerleading 😂😂😂
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 16 at 1:49 PM
$ABCL South Korea likes $ABCL https://x.com/nick88886666/status/2044669284224483720?s=20
0 · Reply
Targhee
Targhee Apr. 16 at 1:46 PM
$ABCL enough is enough…BLOCKED!!
2 · Reply
tradersunion353
tradersunion353 Apr. 16 at 1:44 PM
$ABCL market is trading at record highs meanwhile this pos overhyped stock cannot even move a penny .
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 16 at 1:42 PM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 16 at 1:41 PM
$ABCL Truist on $ABCL https://x.com/jinseongeo83473/status/2044693047402004887?s=20
0 · Reply
Rastafari
Rastafari Apr. 15 at 11:36 PM
$ABCL HSBC increase their holdings of the stock by over 300% in March!
3 · Reply
DragonAlgo
DragonAlgo Apr. 15 at 10:16 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com
0 · Reply
WenMoon9
WenMoon9 Apr. 15 at 3:25 PM
$ABCL
1 · Reply
tradersunion353
tradersunion353 Apr. 15 at 2:56 PM
$ABCL How is adding and loading at 3 dollars for last 3 years working ? LMOAF Junk does not move at all.
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Apr. 15 at 2:42 PM
$ABCL It will be a slow climb to probably $5-$7 until the read out in Q3. If its successful this will tear because it proves the discovery platform works. If it fails we go to $0. If I were management I wouldnt be all in like this unless I was confident in my platform.
1 · Reply
DeMampCamp
DeMampCamp Apr. 15 at 1:03 PM
$ABCL Volume precedes price!
0 · Reply
Art_BunyaaHa
Art_BunyaaHa Apr. 15 at 4:00 AM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 15 at 2:50 AM
$ABCL https://www.gurufocus.com/news/8787149/abcellera-biologics-abcl-new-buy-rating-from-jones-trading-abcl-stock-news?mobile=true
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 15 at 2:43 AM
$ABCL https://finance.yahoo.com/sectors/healthcare/articles/abcellera-biologics-abcl-committed-leverage-055935743.html
0 · Reply
Rastafari
Rastafari Apr. 14 at 11:56 PM
$ABCL Good chance we break $4 this week
0 · Reply
tradersunion353
tradersunion353 Apr. 14 at 6:29 PM
$ABCL This overhyped underperforming stock must have been trading above $5 without even news... Mean while who are married to stock, always want to see this trading at 3 dollars are like
0 · Reply
Instwr
Instwr Apr. 14 at 6:00 PM
$ABCL let’s push ⬆️
0 · Reply